2024
Lipid-Lowering Therapy Use When Indicated and Subsequent Ischemic Stroke Severity.
Gordon-Kundu B, Peyravi R, Garg A, Baker A, Salas S, Levien M, Faridi K, de Havenon A, Krumholz H, Sheth K, Forman R, Sharma R. Lipid-Lowering Therapy Use When Indicated and Subsequent Ischemic Stroke Severity. Journal Of The American Heart Association 2024, 14: e033365. PMID: 39699007, DOI: 10.1161/jaha.123.033365.Peer-Reviewed Original ResearchConceptsPrescribed lipid-lowering therapyNational Institutes of Health Stroke Scale scoreAcute ischemic strokeLipid-lowering therapyStroke Scale scoreStroke severityGuidelines-Stroke registryAtherosclerotic cardiovascular disease eventsCardiovascular disease eventsScale scoreGuideline-recommended criteriaSevere stroke symptomsStudy assessed usePropensity score subclassificationLipid-lowering therapy useNational InstituteLogistic regression modelsCholesterol management guidelinesPoststroke disabilityElevated low-density lipoprotein cholesterolInstitutional GetSmall vessel diseaseTime of acute ischemic strokeLarge-artery atherosclerosisLow-density lipoprotein cholesterol
2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claims
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply